Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?

Ridker PM.

Curr Atheroscler Rep. 2013 Jan;15(1):295. doi: 10.1007/s11883-012-0295-3. Review.

3.
4.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
5.

Inflammation, C-reactive protein, and atherothrombosis.

Ridker PM, Silvertown JD.

J Periodontol. 2008 Aug;79(8 Suppl):1544-51. doi: 10.1902/jop.2008.080249. Review.

PMID:
18673009
6.

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS.

JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985. Review.

PMID:
27673306
7.

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).

Ridker PM.

J Thromb Haemost. 2009 Jul;7 Suppl 1:332-9. doi: 10.1111/j.1538-7836.2009.03404.x. Review.

8.
9.

High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.

Koenig W.

Int J Cardiol. 2013 Oct 15;168(6):5126-34. doi: 10.1016/j.ijcard.2013.07.113. Epub 2013 Aug 24. Review.

PMID:
23978367
10.

Intensive statin therapy for Indians: Part-I. Benefits.

Enas EA, Pazhoor HC, Kuruvila A, Vijayaraghavan K.

Indian Heart J. 2011 May-Jun;63(3):211-27. Review.

PMID:
22734339
11.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
12.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
13.
14.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280
15.

Interpretation of the evidence for the efficacy and safety of statin therapy.

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R.

Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8. Review.

PMID:
27616593
16.

High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?

Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, Blumenthal RS, Budoff MJ.

J Am Coll Cardiol. 2013 Jul 30;62(5):397-408. doi: 10.1016/j.jacc.2013.05.016. Epub 2013 May 30. Review.

17.

The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

O'Keefe JH, Carter MD, Lavie CJ, Bell DS.

Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Review.

PMID:
19491548
18.

Therapeutic options to further lower C-reactive protein for patients on statin treatment.

Joshi PH, Jacobson TA.

Curr Atheroscler Rep. 2010 Jan;12(1):34-42. doi: 10.1007/s11883-009-0075-x. Review.

PMID:
20425269
19.
20.

The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines.

Mora S, Musunuru K, Blumenthal RS.

Clin Chem. 2009 Feb;55(2):219-28. doi: 10.1373/clinchem.2008.109728. Epub 2008 Dec 18. Review.

Supplemental Content

Support Center